These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 33171304)
1. HDAC6 as privileged target in drug discovery: A perspective. Pulya S; Amin SA; Adhikari N; Biswas S; Jha T; Ghosh B Pharmacol Res; 2021 Jan; 163():105274. PubMed ID: 33171304 [TBL] [Abstract][Full Text] [Related]
2. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors. Tavares MT; Kozikowski AP; Shen S Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922 [TBL] [Abstract][Full Text] [Related]
3. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Lernoux M; Schnekenburger M; Dicato M; Diederich M Pharmacol Res; 2018 Mar; 129():337-356. PubMed ID: 29133216 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in the discovery of potent and selective HDAC6 inhibitors. Wang XX; Wan RZ; Liu ZP Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060 [TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy. Shetty MG; Pai P; Deaver RE; Satyamoorthy K; Babitha KS Pharmacol Res; 2021 Aug; 170():105695. PubMed ID: 34082029 [TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Drug Design of Selective HDAC6 Inhibitors. Ruzic D; Djokovic N; Nikolic K Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126 [TBL] [Abstract][Full Text] [Related]
8. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia. Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502 [TBL] [Abstract][Full Text] [Related]
9. Role of histone deacetylases and their inhibitors in neurological diseases. Zhang LY; Zhang SY; Wen R; Zhang TN; Yang N Pharmacol Res; 2024 Oct; 208():107410. PubMed ID: 39276955 [TBL] [Abstract][Full Text] [Related]
10. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019). He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106 [TBL] [Abstract][Full Text] [Related]
11. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
12. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease. Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679 [TBL] [Abstract][Full Text] [Related]
13. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors. Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291 [TBL] [Abstract][Full Text] [Related]
14. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? Amin SA; Adhikari N; Jha T Pharmacol Res; 2017 Aug; 122():8-19. PubMed ID: 28501516 [TBL] [Abstract][Full Text] [Related]
15. An assessment of crucial structural contributors of HDAC6 inhibitors through fragment-based non-linear pattern recognition and molecular dynamics simulation approaches. Banerjee S; Jana S; Jha T; Ghosh B; Adhikari N Comput Biol Chem; 2024 Jun; 110():108051. PubMed ID: 38520883 [TBL] [Abstract][Full Text] [Related]
16. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes. Osko JD; Christianson DW Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087 [TBL] [Abstract][Full Text] [Related]
18. Do biological activities of selective histone deacetylase 6 (HDAC6) inhibitors rely on the modification of cap group? Liu X; Wang S; Shi X; Lu M; Wang C; Li X; Zhang Y; Jia Q; Liu H J Mol Recognit; 2022 Dec; 35(12):e2988. PubMed ID: 36054561 [TBL] [Abstract][Full Text] [Related]
19. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics. Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262 [TBL] [Abstract][Full Text] [Related]
20. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019). Shen S; Kozikowski AP Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813 [No Abstract] [Full Text] [Related] [Next] [New Search]